PMID- 32074411 OWN - NLM STAT- MEDLINE DCOM- 20210621 LR - 20210621 IS - 2055-5822 (Electronic) IS - 2055-5822 (Linking) VI - 7 IP - 2 DP - 2020 Apr TI - Sacubitril/valsartan in patients listed for heart transplantation: effect on physical frailty. PG - 757-762 LID - 10.1002/ehf2.12610 [doi] AB - AIMS: The aim of this study was to investigate prospectively the effect of sacubitril/valsartan in advanced heart failure (HF) patients in waiting list for heart transplantation (HT) and the effect on physical frailty (PF). METHODS AND RESULTS: We treated 37 consecutive patients with advanced HF with sacubitril/valsartan. Patients were followed up until HT, device implant, or last follow-up visit after 2 years of follow-up. At baseline, mean New York Heart Association (NYHA) class was 3.1 +/- 0.4, with 64.9% in NYHA III and 35.1% NYHA IIIB. Left ventricular ejection fraction was 23.5 +/- 5.8%, VO(2) max was 10.3 +/- 2.3 mL/kg/min, cardiac index was 2.3 +/- 0.5 L/min/m(2) , and N-terminal pro-brain natriuretic peptide (NT-pro-BNP) was 4943.0 +/- 5326.8 pg/mL. After a mean follow-up of 17.1 +/- 4.4 months, no deaths were observed, but NYHA class improved significantly with 56.8% in NYHA II, 40.5% in NYHA III, and 2.7% in NYHA IIIB (P < 0.001). VO(2) max and 6 min walk test (6MWT) increased, whereas pulmonary systolic blood pressure, E/E', VE/VCO(2) slope, and NT-pro-BNP decreased. At right heart catheterization performed after 1 year of follow-up, cardiac index and pulmonary vascular resistance remained stable, while a decrease in systolic pulmonary artery pressure and pulmonary capillary wedge pressure is observed. Furosemide dosage decrease from 102.7 +/- 69.4 to 78.7 +/- 66.3 mg (P = 0.040). PF decreased from 3.35 +/- 1.0 at baseline to 1.57 +/- 1.3 at the end of follow-up (P < 0.001), with a reduction in all PF domains. CONCLUSIONS: Our study showed a rapid improvement in PF in HT waiting list patients treated with sacubitril/valsartan. The improvement in all PF domains was paralleled by VO(2) and 6MWT increase and together with an NT-pro-BNP reduction constant over the follow-up. CI - (c) 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. FAU - Cacciatore, Francesco AU - Cacciatore F AD - Department of Translational Medical Sciences, University of Naples 'Federico II', 80131, Naples, Italy. AD - Department of Cardiovascular Surgery and Transplant, Monaldi Hospital, Azienda dei Colli, 80131, Naples, Italy. FAU - Amarelli, Cristiano AU - Amarelli C AD - Department of Cardiovascular Surgery and Transplant, Monaldi Hospital, Azienda dei Colli, 80131, Naples, Italy. FAU - Maiello, Ciro AU - Maiello C AD - Department of Cardiovascular Surgery and Transplant, Monaldi Hospital, Azienda dei Colli, 80131, Naples, Italy. FAU - Mattucci, Irene AU - Mattucci I AD - Department of Cardiovascular Surgery and Transplant, Monaldi Hospital, Azienda dei Colli, 80131, Naples, Italy. FAU - Salerno, Gemma AU - Salerno G AD - Department of Cardiovascular Surgery and Transplant, Monaldi Hospital, Azienda dei Colli, 80131, Naples, Italy. FAU - Di Maio, Marco AU - Di Maio M AD - Department of Cardiology, Universita degli Studi della Campania 'Luigi Vanvitelli', Monaldi Hospital, 80131, Naples, Italy. FAU - Palmieri, Vittorio AU - Palmieri V AD - Department of Cardiovascular Surgery and Transplant, Monaldi Hospital, Azienda dei Colli, 80131, Naples, Italy. FAU - Curcio, Francesco AU - Curcio F AD - Department of Translational Medical Sciences, University of Naples 'Federico II', 80131, Naples, Italy. FAU - Pirozzi, Flora AU - Pirozzi F AD - Department of Translational Medical Sciences, University of Naples 'Federico II', 80131, Naples, Italy. FAU - Mercurio, Valentina AU - Mercurio V AD - Department of Translational Medical Sciences, University of Naples 'Federico II', 80131, Naples, Italy. FAU - Benincasa, Giuditta AU - Benincasa G AD - University Department of Advanced Medical and Surgical Sciences, Clinical Department of Internal and Specialty Medicine (DAI), Universita degli Studi della Campania 'Luigi Vanvitelli', 80138, Naples, Italy. FAU - Golino, Paolo AU - Golino P AD - Department of Cardiology, Universita degli Studi della Campania 'Luigi Vanvitelli', Monaldi Hospital, 80131, Naples, Italy. FAU - Bonaduce, Domenico AU - Bonaduce D AD - Department of Translational Medical Sciences, University of Naples 'Federico II', 80131, Naples, Italy. FAU - Napoli, Claudio AU - Napoli C AD - University Department of Advanced Medical and Surgical Sciences, Clinical Department of Internal and Specialty Medicine (DAI), Universita degli Studi della Campania 'Luigi Vanvitelli', 80138, Naples, Italy. FAU - Abete, Pasquale AU - Abete P AD - Department of Translational Medical Sciences, University of Naples 'Federico II', 80131, Naples, Italy. LA - eng PT - Journal Article DEP - 20200219 PL - England TA - ESC Heart Fail JT - ESC heart failure JID - 101669191 RN - 0 (Aminobutyrates) RN - 0 (Biphenyl Compounds) RN - 0 (Drug Combinations) RN - 80M03YXJ7I (Valsartan) RN - WB8FT61183 (sacubitril and valsartan sodium hydrate drug combination) SB - IM MH - Aminobutyrates MH - Biphenyl Compounds MH - Drug Combinations MH - *Frailty MH - *Heart Transplantation MH - Humans MH - Stroke Volume MH - Valsartan MH - Ventricular Function, Left PMC - PMC7160499 OTO - NOTNLM OT - Frailty OT - Heart Failure OT - Sacubitril/Valsartan COIS- None of the authors have a conflict of interest in the connection with the present study (which includes honorary fee, consultancy, or other profits from the industries producing the drug). EDAT- 2020/02/20 06:00 MHDA- 2021/06/22 06:00 PMCR- 2020/02/19 CRDT- 2020/02/20 06:00 PHST- 2019/07/19 00:00 [received] PHST- 2019/10/29 00:00 [revised] PHST- 2019/12/09 00:00 [accepted] PHST- 2020/02/20 06:00 [pubmed] PHST- 2021/06/22 06:00 [medline] PHST- 2020/02/20 06:00 [entrez] PHST- 2020/02/19 00:00 [pmc-release] AID - EHF212610 [pii] AID - 10.1002/ehf2.12610 [doi] PST - ppublish SO - ESC Heart Fail. 2020 Apr;7(2):757-762. doi: 10.1002/ehf2.12610. Epub 2020 Feb 19.